Completed NA INTERVENTIONAL 1-arm NCT01541865

Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN)

Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN) - POST MARKET APPROVAL CLINICAL SURVEILLANCE STUDY

Sponsor: Boston Scientific Corporation

Conditions Hypertension

Interventions Renal Denervation

Updated 6 times since 2017 Last updated: Oct 23, 2015 Started: Feb 29, 2012 Primary completion: Nov 30, 2013 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Hypertension and is currently completed. Boston Scientific Corporation leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boston Scientific Corporation

Data source: Boston Scientific Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Adelaide, Australia , Amsterdam, Netherlands , Auckland, New Zealand , Bad Berka, Germany , Bad Soden/Taunus, Germany , Bedford Park, Australia , Berlin, Germany , Brisbane, Australia , Brussels, Belgium and 16 more locations